Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 30;26(2):281-288.
doi: 10.5056/jnm19050.

Treatment Pattern and Economic Burden of Refractory Gastroesophageal Reflux Disease Patients in Korea

Affiliations
Free PMC article

Treatment Pattern and Economic Burden of Refractory Gastroesophageal Reflux Disease Patients in Korea

Susan Park et al. J Neurogastroenterol Motil. .
Free PMC article

Abstract

Background/aims: The prevalence of gastroesophageal reflux disease (GERD) has increased in Korea, and the economic burden of this chronic disease is substantial. We aim to investigate the treatment pattern and economic burden in Korea of refractory GERD requiring long-term use of proton pump inhibitors (PPIs).

Methods: We conducted a cross-sectional analysis of nationally representative sample data obtained from 2012 to 2016 and provided by the Health Insurance Review and Assessment Service. The participants were 86 936 in the medication group and 40 in the surgery group. Age- and sex-standardized prevalence of refractory GERD requiring PPIs medication for more than 12 weeks were analyzed. Generalized linear models were used to estimate cost ratios for comparing the medical costs of the surgery and medication groups after adjustment for demographics and comorbidity.

Results: The prevalence of refractory GERD increased from 1.2% in 2012 to 1.9% in 2016, and the estimated total number of GERD patients increased from 402 000 to 736 000 during this time period. The medical expenditures of the surgery group within 90 days of antireflux surgery (ARS) were 16.9-fold higher compared to those of the medication group; the significant difference in medical costs between the 2 groups disappeared after 90 days post-surgery.

Conclusions: The prevalence of refractory GERD requiring long-term use of PPIs has been trending upwards recently. Nevertheless, ARS is very rarely performed. Considering the increasing medical costs of long-term PPI use, further cost-effectiveness analysis is needed to compare ARS and PPI therapy for the treatment of GERD in Korea.

Keywords: Fundoplication; Gastroesophageal reflux; Proton pump inhibitors.

Conflict of interest statement

Conflicts of interest: None.

Figures

Figure 1
Figure 1
Flow chart for the study population selection procedure. (A) Medication group. (B) Surgery group. HIRA-NIS, the Health Insurance Review and Assessment Service-National Inpatient Sample; HIRA-NPS, the Health Insurance Review and Assessment Service-National Patient Sample; PPI, proton pump inhibitor.
Figure 2
Figure 2
Age- and sex-standardized prevalence and estimated number of patients prescribed proton pump inhibitors (PPIs) for more than 12 weeks.
Figure 3
Figure 3
Age- and sex-specific prevalence of patients prescribed proton pump inhibitors (PPIs) for more than 12 weeks. (A) Sex-specific prevalence. (B) Age-specific prevalence.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430–440. doi: 10.1136/gutjnl-2016-313589. - DOI - PubMed
    1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880. doi: 10.1136/gutjnl-2012-304269. - DOI - PMC - PubMed
    1. Kim KM, Cho YK, Bae SJ, et al. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study. J Gastroenterol Hepatol. 2012;27:741–745. doi: 10.1111/j.1440-1746.2011.06921.x. - DOI - PubMed
    1. Min BH, Huh KC, Jung HK, et al. Prevalence of uninvestigated dyspepsia and gastroesophageal reflux disease in Korea: a population-based study using the Rome III criteria. Dig Dis Sci. 2014;59:2721–2729. doi: 10.1007/s10620-014-3243-y. - DOI - PubMed
    1. Gawron AJ, French DD, Pandolfino JE, Howden CW. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32:745–758. doi: 10.1007/s40273-014-0164-8. - DOI - PMC - PubMed

LinkOut - more resources

Feedback